[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

DE602006009631D1 - GLP-1 Peptide enthaltende kugelförmige Mikrokapseln, deren Produktion und deren Verwendung - Google Patents

GLP-1 Peptide enthaltende kugelförmige Mikrokapseln, deren Produktion und deren Verwendung

Info

Publication number
DE602006009631D1
DE602006009631D1 DE602006009631T DE602006009631T DE602006009631D1 DE 602006009631 D1 DE602006009631 D1 DE 602006009631D1 DE 602006009631 T DE602006009631 T DE 602006009631T DE 602006009631 T DE602006009631 T DE 602006009631T DE 602006009631 D1 DE602006009631 D1 DE 602006009631D1
Authority
DE
Germany
Prior art keywords
production
spherical microcapsules
diseases
conditions associated
glp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE602006009631T
Other languages
English (en)
Inventor
Peter Dr Geigle
Christine Dr Wallrapp
Eric Thoenes
Frank Dr Thuermer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biocompatibles UK Ltd
Original Assignee
Biocompatibles UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocompatibles UK Ltd filed Critical Biocompatibles UK Ltd
Publication of DE602006009631D1 publication Critical patent/DE602006009631D1/de
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5052—Proteins, e.g. albumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/32—Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/35—Fat tissue; Adipocytes; Stromal cells; Connective tissues
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0653—Adipocytes; Adipose tissue
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/126—Immunoprotecting barriers, e.g. jackets, diffusion chambers
    • A61K2035/128—Immunoprotecting barriers, e.g. jackets, diffusion chambers capsules, e.g. microcapsules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/33—Insulin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/38—Hormones with nuclear receptors
    • C12N2501/39—Steroid hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/04—Immortalised cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
DE602006009631T 2006-05-10 2006-05-10 GLP-1 Peptide enthaltende kugelförmige Mikrokapseln, deren Produktion und deren Verwendung Expired - Fee Related DE602006009631D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06009678A EP1854455B1 (de) 2006-05-10 2006-05-10 GLP-1 Peptide enthaltende kugelförmige Mikrokapseln, deren Produktion und deren Verwendung

Publications (1)

Publication Number Publication Date
DE602006009631D1 true DE602006009631D1 (de) 2009-11-19

Family

ID=37773605

Family Applications (2)

Application Number Title Priority Date Filing Date
DE602006009631T Expired - Fee Related DE602006009631D1 (de) 2006-05-10 2006-05-10 GLP-1 Peptide enthaltende kugelförmige Mikrokapseln, deren Produktion und deren Verwendung
DE602007013385T Active DE602007013385D1 (de) 2006-05-10 2007-04-27 Sphärische oder nichtsphärische mikrokapseln mit glp-1-peptiden, ihre herstellung und verwendung

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE602007013385T Active DE602007013385D1 (de) 2006-05-10 2007-04-27 Sphärische oder nichtsphärische mikrokapseln mit glp-1-peptiden, ihre herstellung und verwendung

Country Status (13)

Country Link
US (2) US8790705B2 (de)
EP (3) EP1854455B1 (de)
JP (1) JP5209608B2 (de)
CN (1) CN101489539A (de)
AT (2) ATE444741T1 (de)
AU (1) AU2007247511B2 (de)
CA (1) CA2649902A1 (de)
DE (2) DE602006009631D1 (de)
DK (1) DK2015736T3 (de)
ES (1) ES2363810T3 (de)
PL (1) PL2015736T3 (de)
PT (1) PT2015736E (de)
WO (1) WO2007128443A2 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1767545E (pt) 2005-09-22 2010-02-05 Biocompatibles Uk Ltd Polipéptidos de fusão glp-1 (péptido 1 do tipo glucagom) com resistência aumentada à peptidase
DE602006009631D1 (de) * 2006-05-10 2009-11-19 Biocompatibles Uk Ltd GLP-1 Peptide enthaltende kugelförmige Mikrokapseln, deren Produktion und deren Verwendung
EP1972349A1 (de) * 2007-03-21 2008-09-24 Biocompatibles UK Limited Mit Polymer(en) konjugierte GLP-1-Fusionspeptide, ihre Herstellung und Verwendung
EP1975176A1 (de) * 2007-03-27 2008-10-01 Biocompatibles UK Limited Neue GLP-1-Fusionspeptide, ihre Herstellung und Verwendung
WO2009007979A2 (en) * 2007-07-11 2009-01-15 Technion Research & Development Foundation Ltd. Encapsulated mesenchymal stem cells and uses thereof
EP2163243A1 (de) * 2008-09-12 2010-03-17 Biocompatibles UK Limited Behandlung akuter Herzinfarkte mithilfe eingekapselter Zellen, welche GLP-1-Peptide oder deren Analoga kodieren und absondern
EP2251028A1 (de) * 2009-05-12 2010-11-17 Biocompatibles Uk Ltd. Behandlung von Augenerkrankungen unter Verwendung eingekapselter Zellen, die einen antiangiogenetischen Faktor und/oder einen neuroprotektiven Faktor codieren und sekretieren
US20120020931A1 (en) 2010-06-02 2012-01-26 Rutgers, The State University Of New Jersey Therapeutic encapsulated embryonic stem cells and mesenchymal stromal cells
US20140004201A1 (en) * 2010-09-15 2014-01-02 Biocompatibles Uk Ltd. Treatment of Vascular Diseases Using Encapsulated Cells Encoding and Secreting GLP-1, or a Fragment or Variant Thereof
EP2665433B1 (de) 2011-01-19 2021-03-10 Fractyl Laboratories Inc. Vorrichtungen zur gewebebehandlung
MX2013011040A (es) * 2011-03-29 2014-08-22 Beta Cell Nv Metodo para productos terapeuticos encapsulados y usos de los mismos.
WO2012155209A1 (en) * 2011-05-19 2012-11-22 Mesoblast, Inc Methods for treating obesity and/or metabolic syndrome
KR101335176B1 (ko) * 2011-12-12 2013-11-29 테고사이언스 (주) 상처 치유용 드레싱재제
WO2013130655A1 (en) 2012-02-27 2013-09-06 Fractyl Laboratories, Inc. Heat ablation systems, devices and methods for the treatment of tissue
JP6235559B2 (ja) 2012-04-19 2017-11-22 フラクティル ラボラトリーズ インコーポレイテッド 組織拡張デバイス、システムおよび方法
EP3714826A1 (de) 2012-07-30 2020-09-30 Fractyl Laboratories, Inc. Systeme und vorrichtungen zur ablation und behandlung von gewebe
WO2014026055A1 (en) 2012-08-09 2014-02-13 Fractyl Laboratories Inc. Ablation systems, devices and methods for the treatment of tissue
EP2903626A4 (de) 2012-10-05 2016-10-19 Fractyl Lab Inc Verfahren, systeme und vorrichtungen zur durchführung mehrerer behandlungen eines patienten
WO2014197632A2 (en) 2013-06-04 2014-12-11 Fractyl Laboratories, Inc. Methods, systems and devices for reducing the luminal surface area of the gastrointestinal tract
EP3043732B1 (de) 2013-09-12 2021-04-07 Fractyl Laboratories, Inc. Systeme und vorrichtungen zur behandlung von zielgewebe
AU2014352874B2 (en) * 2013-11-22 2019-03-14 Fractyl Health, Inc. Systems, devices and methods for the creation of a therapeutic restriction in the gastrointestinal tract
CN104805058A (zh) * 2014-01-23 2015-07-29 上海欧易生物医学科技有限公司 一种稳定表达外源性glp-1基因的人脐带源间充质干细胞株
US10959774B2 (en) 2014-03-24 2021-03-30 Fractyl Laboratories, Inc. Injectate delivery devices, systems and methods
US11185367B2 (en) 2014-07-16 2021-11-30 Fractyl Health, Inc. Methods and systems for treating diabetes and related diseases and disorders
EP3169260B1 (de) 2014-07-16 2019-09-25 Fractyl Laboratories, Inc. System zur behandlung von diabetes und zugehöriger erkrankungen und störungen
US9757535B2 (en) 2014-07-16 2017-09-12 Fractyl Laboratories, Inc. Systems, devices and methods for performing medical procedures in the intestine
TWI726889B (zh) * 2015-06-10 2021-05-11 英商梅迪繆思有限公司 蛋白酶抗性之脂化肽
AU2016379403B2 (en) 2015-12-23 2020-03-12 The Johns Hopkins University Long-acting GLP-1r agonist as a therapy of neurological and neurodegenerative conditions
CN111518770B (zh) * 2017-12-19 2023-01-06 北京吉源生物科技有限公司 一种表达glp1和fgf21的干细胞及其用途
CN111803617A (zh) * 2020-07-16 2020-10-23 卡杜兰(广州)生命基因工程科技有限公司 一种内载微囊的干细胞系统与制备方法
US12122817B2 (en) * 2020-09-22 2024-10-22 Serpentide Inc. Long-lasting GLP1 analogue drug for type-2 diabetes
CN113493764B (zh) * 2021-07-27 2023-01-24 新乡医学院 一种体外诱导小鼠耳朵间充质干细胞分化为脂肪细胞的方法
WO2023028554A1 (en) * 2021-08-25 2023-03-02 Neuraly, Inc. Glp-1r agonists for use in a treatment of neurological impairment associated with viral infection

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4352883A (en) * 1979-03-28 1982-10-05 Damon Corporation Encapsulation of biological material
US4596792A (en) 1981-09-04 1986-06-24 The Regents Of The University Of California Safe vaccine for hepatitis containing polymerized serum albumin
JPS5938877A (ja) 1982-08-30 1984-03-02 Musashi Eng Kk 紙葉判別方法
US4599230A (en) 1984-03-09 1986-07-08 Scripps Clinic And Research Foundation Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
US4599231A (en) 1984-03-09 1986-07-08 Scripps Clinic And Research Foundation Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
US4608251A (en) 1984-11-09 1986-08-26 Pitman-Moore, Inc. LHRH analogues useful in stimulating anti-LHRH antibodies and vaccines containing such analogues
US4601903A (en) 1985-05-01 1986-07-22 The United States Of America As Represented By The Department Of Health And Human Services Vaccine against Neisseria meningitidis Group B serotype 2 invasive disease
US6849708B1 (en) * 1986-05-05 2005-02-01 The General Hospital Corporation Insulinotropic hormone and uses thereof
CA2096418C (en) 1990-11-26 2001-11-20 Philip J. Barr Expression of pace in host cells and methods of use thereof
US5270181A (en) 1991-02-06 1993-12-14 Genetics Institute, Inc. Peptide and protein fusions to thioredoxin and thioredoxin-like molecules
ES2087323T3 (es) * 1991-02-19 1996-07-16 Takeda Chemical Industries Ltd Metodo para producir peptidos exentos de cisteina.
GB9311147D0 (en) 1993-05-28 1993-07-14 Long Ashton Research Station Regulation of plant growth
UA70283C2 (en) 1996-03-01 2004-10-15 Novo Nordisk As Peptide (variants), a pharmaceutical composition cpeptide (variants), a pharmaceutical composition composed of peptide and a method for the preparatioomposed of peptide and a method for the preparation thereof (variants) n thereof (variants)
PT966297E (pt) * 1996-08-08 2009-03-18 Amylin Pharmaceuticals Inc Regulação da motilidade gastrintestinal
US5830723A (en) 1996-08-13 1998-11-03 Regents Of The University Of Minnesota Method for immortalizing chicken cells
HU227021B1 (en) 1996-08-30 2010-05-28 Novo Nordisk As Glp-1 derivatives
WO1998020895A1 (en) 1996-11-12 1998-05-22 Novo Nordisk A/S Use of glp-1 peptides
CA2318379A1 (en) 1998-01-12 1999-07-15 Betagene, Inc. Identification of substances that modify cellular secretory function
NZ506839A (en) 1998-03-09 2003-05-30 Zealand Pharma As Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
AU3047299A (en) * 1998-04-13 1999-11-01 Modex Therapeutiques, S.A. Methods of delivering glp-1
DE19836960A1 (de) 1998-08-14 2000-02-17 Ulrich Zimmermann Verfahren zur Gewinnung hochgereinigter Alginate
US7259136B2 (en) * 1999-04-30 2007-08-21 Amylin Pharmaceuticals, Inc. Compositions and methods for treating peripheral vascular disease
DE19904785A1 (de) 1999-02-05 2000-08-10 Ulrich Zimmermann Verfahren zur Herstellung von stabilem Alginatmaterial
US6267954B1 (en) * 1999-11-24 2001-07-31 Universite De Paris V Rene-Descartes Intraocular transplantation of encapsulated cells
ATE309818T1 (de) 2000-03-08 2005-12-15 Novo Nordisk As Senkung des serum cholesterols
CZ308214B6 (cs) 2000-12-07 2020-03-04 Eli Lilly And Company GLP-1 fúzní proteiny
US20020183253A1 (en) 2001-02-22 2002-12-05 Brazzell Romulus Kimbro Method of treating ocular neovascularization
US20030119734A1 (en) * 2001-06-28 2003-06-26 Flink James M. Stable formulation of modified GLP-1
CN1363654A (zh) * 2001-07-19 2002-08-14 上海华谊生物技术有限公司 生产促胰岛素分泌肽glp－1(7－36)的基因工程菌以及生产glp－1(7－36)的方法
WO2003010305A1 (en) 2001-07-27 2003-02-06 Arhus Amt Immortilized stem cells
ATE536881T1 (de) 2001-07-31 2011-12-15 Us Gov Health & Human Serv Glp-1, exendin-4, peptid-analoga und verwendungen davon
US20040143104A1 (en) * 2001-08-08 2004-07-22 Wadsworth Samuel C. Methods of treating diabetes and other blood sugar disorders
US7238663B2 (en) 2001-08-28 2007-07-03 Eli Lilly And Company Pre-mixes of GLP-1 and basal insulin
US7176278B2 (en) * 2001-08-30 2007-02-13 Biorexis Technology, Inc. Modified transferrin fusion proteins
WO2003059372A2 (en) * 2001-12-29 2003-07-24 Novo Nordisk A/S Combined use of a glp-1 compound and a modulator of diabetic late complications
AU2003200839B2 (en) 2002-01-08 2008-12-11 Eli Lilly And Company Extended glucagon-like peptide-1 analogs
US20030191056A1 (en) 2002-04-04 2003-10-09 Kenneth Walker Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
AU2003273300A1 (en) * 2002-09-06 2004-03-29 Bayer Pharmaceuticals Corporation Modified glp-1 receptor agonists and their pharmacological methods of use
WO2004078195A1 (ja) 2003-03-07 2004-09-16 Ajinomoto Co., Inc. 腸管細胞のインスリン産生細胞への変換誘導剤、及び糖尿病治療剤
WO2005014035A2 (en) 2003-08-08 2005-02-17 Novo Nordisk Health Care Ag Use of galactose oxidase for selective chemical conjugation of protractor molecules to proteins of therapeutic interest
JP2007508250A (ja) 2003-10-10 2007-04-05 ノボ　ノルディスク　アクティーゼルスカブ 持続性放出製剤における長期作用性分子
MXPA06006746A (es) 2003-12-18 2006-08-18 Novo Nordisk As Analogos de glp-1 novedosos ligados a agentes similares a albumina.
AU2005211755B2 (en) 2004-02-11 2012-03-15 Amylin Pharmaceuticals, Llc Hybrid polypeptides with selectable properties
JP2008537873A (ja) 2004-03-31 2008-10-02 セントカー・インコーポレーテツド ヒトｇｌｐ−１ミメティボディ、組成物、方法および用途
WO2006010143A2 (en) 2004-07-13 2006-01-26 Neose Technologies, Inc. Branched peg remodeling and glycosylation of glucagon-like peptide-1 [glp-1]
US7442682B2 (en) 2004-10-19 2008-10-28 Nitto Denko Corporation Transepithelial delivery of peptides with incretin hormone activities
AU2006279276A1 (en) 2005-07-29 2007-02-15 Amprotein Corporation Chimeric therapeutic agents
PT1767545E (pt) 2005-09-22 2010-02-05 Biocompatibles Uk Ltd Polipéptidos de fusão glp-1 (péptido 1 do tipo glucagom) com resistência aumentada à peptidase
DE602006009631D1 (de) * 2006-05-10 2009-11-19 Biocompatibles Uk Ltd GLP-1 Peptide enthaltende kugelförmige Mikrokapseln, deren Produktion und deren Verwendung
EP1972349A1 (de) * 2007-03-21 2008-09-24 Biocompatibles UK Limited Mit Polymer(en) konjugierte GLP-1-Fusionspeptide, ihre Herstellung und Verwendung
EP1975176A1 (de) * 2007-03-27 2008-10-01 Biocompatibles UK Limited Neue GLP-1-Fusionspeptide, ihre Herstellung und Verwendung
EP2163243A1 (de) 2008-09-12 2010-03-17 Biocompatibles UK Limited Behandlung akuter Herzinfarkte mithilfe eingekapselter Zellen, welche GLP-1-Peptide oder deren Analoga kodieren und absondern

Also Published As

Publication number Publication date
US20100068289A1 (en) 2010-03-18
ES2363810T3 (es) 2011-08-17
US20140105991A1 (en) 2014-04-17
EP1854455B1 (de) 2009-10-07
AU2007247511A1 (en) 2007-11-15
CN101489539A (zh) 2009-07-22
ATE502628T1 (de) 2011-04-15
EP2015736A2 (de) 2009-01-21
PT2015736E (pt) 2011-05-30
EP2015736B1 (de) 2011-03-23
AU2007247511B2 (en) 2012-12-06
WO2007128443A3 (en) 2008-05-22
WO2007128443A2 (en) 2007-11-15
DK2015736T3 (da) 2011-06-14
ATE444741T1 (de) 2009-10-15
JP5209608B2 (ja) 2013-06-12
EP1854455A1 (de) 2007-11-14
CA2649902A1 (en) 2007-11-15
PL2015736T3 (pl) 2011-09-30
DE602007013385D1 (de) 2011-05-05
JP2009536166A (ja) 2009-10-08
EP2174655A1 (de) 2010-04-14
US8790705B2 (en) 2014-07-29

Similar Documents

Publication Publication Date Title
ATE444741T1 (de) Glp-1 peptide enthaltende kugelförmige mikrokapseln, deren produktion und deren verwendung
DOP2009000134A (es) Compuestos bicíclicos y su uso como anti-diabéticos
ATE455783T1 (de) Neue glucopyranoseester und glucofuranoseester von fumarsäurealkylestern und deren pharmazeutische verwendung
WO2004078777A3 (en) Dipeptidyl-peptidase protected proteins
WO2007048122A3 (en) Antibody-based therapeutics with enhanced adcc activity
EA200601313A1 (ru) Варианты участка f
ATE512663T1 (de) Kombination zur behandlung von erkrankungen mit zellproliferation
WO2007022470A3 (en) Methods and compositions for treating neurological disease
GT200800278A (es) Moleculas de enlace multivalente y sus aplicaciones terapeuticas
IL195156A (en) Polypeptides containing human igf-1 protein precursor, their use in the preparation of drugs for the treatment of musculoskeletal disease, nucleic acid encoding the above polypeptides, a vector containing the above nucleic acid and a cell transfected with the above vector
DE602005027093D1 (de) Polypeptide mit lipase-aktivität und diese kodierende polynukleotide
WO2011036442A3 (en) Thrombin c- terminal polypeptides and uses thereof for treating inflammation coagulation disorders
MY157173A (en) Modified humanised anti-interleukin-18
WO2009017655A3 (en) Methods and compositions for stimulating the proliferation or differentiation of stem cells with substance p or an analog thereof
ATE440609T1 (de) Binäre hyaluronsäure-gemische und ihre therapeutische verwendung
WO2006114105A8 (en) Use of modified factor vii for treating bleeding
EA200901067A1 (ru) Использование семафорина 6а в качестве промотора миелинизации и дифференцировки олигодендроцитов
DK2407536T3 (da) Adp-ribosyltransferase-fusionsvariantproteiner
DE602005010047D1 (de) Nervenwachstumsfaktor sezernierende menschliche therapeutische zellen
DE60304695D1 (de) 7-ARYLSULFONAMID-2,3,4,5-TETRAHYDRO-1H-BENZOiDöAZEPINE MIT 5-HT6 REZEPTOR AFFINITÄT ZUR BEHANDLUNG VON ZENTRALNERVENSYSTEMERKRANKUNGEN
EA201200141A1 (ru) Фотокаталитический материал
WO2009115252A3 (de) Substituierte pyrazolamide und ihre verwendung
DE602008000215D1 (de) Aktives Verbundanodenmaterial, Herstellungsverfahren dafür sowie Anode und Lithiumbatterie mit dem Material
WO2008154516A3 (en) Btnl2 fusion protein for t-cell activity modulation
ATE416192T1 (de) Protein, das sich an die zelloberflächenschichten bindet, und dessen verwendung

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee